Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis

American Journal of Kidney Diseases

Volumn 39, Issue 4, 2002, Pages 695-705

  Hamano, Kazumasa ^a,b   Iwano, Masayuki ^a,b   Akai, Yasuhiro ^a,b   Sato, Hiroaki ^a,b   Kubo, Atsushi ^a,b   Nishitani, Yoshiharu ^a,b   Uyama, Hideto ^a,b   Yoshida, Yukiko ^a,b   Miyazaki, Masanobu ^a,b   Shiiki, Hideo ^a,b   Kohno, Shigeru ^a,b   Dohi, Kazuhiro ^a,b  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Focal segmental glomerulosclerosis (FSGS); Membranous nephropathy (MN); Plasminogen activator inhibitor type 1 (PAI 1); Tissue plasminogen activator (tPA)

Indexed keywords

ALBUMIN; CHOLESTEROL; COMPLEMENTARY DNA; CREATININE; FIBRIN; MESSENGER RNA; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; FIBRINOLYSIS; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; GLOMERULUS BASEMENT MEMBRANE; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; PATHOGENESIS; POLYMERASE CHAIN REACTION; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN DEGRADATION; PROTEINURIA;

EID: 0036195931     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1103/PhysRevA.64.043603     Document Type: Article

References (55)

1. Coagulation and renal disease
2. The pathogenetic role of the coagulation process in rabbit. Masugi nephritis
3. Primary glomerulonephritis
4. Anticoagulants are of value in the treatment of renal disease
5. Long-term effect of urokinase therapy in IgA nephropathy
6. Tissue plasminogen activator therapy of rabbit nephrotoxic nephritis
7. The progression of renal disease
8. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells
9. Mesangium and glomerular disease
10. Glomerular fibrin deposition and removal
11. Sequential studies of glomerular crescent formation in rats with antiglomerular basement membrane-induced glomerulonephritis and the role of coagulation factors
12. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture
13. Growth factors in the regulation of pericellular proteolysis: A review
14. The plasminogen activator/plasmin system
15. Plasminogen activators, tissue degradation, and cancer
16. Inhibition by anticoagulant drugs of the progressive hypertension and uremia associated with renal infarction in rats
17. Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition
18. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis
19. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene
20. Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies
21. Expression of transforming growth factor-beta isoforms in human glomerular diseases
22. The localization of plasminogen activator inhibitor-1 in glomerular subepithelial deposits in membranous nephropathy
23. Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney
24. Tissue factor, plasminogen activator inhibitor-1, and thrombin receptor expression in human crescentic glomerulonephritis
25. Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syndrome
26. Increased levels of plasminogen activator inhibitor in nephrotic syndrome
27. Intraglomerular expression of transforming growth factor-beta 1 (TGF-beta 1) mRNA in patients with glomerulonephritis: Quantitative analysis by competitive polymerase chain reaction
28. Quantification of glomerular TGF-beta 1 mRNA in patients with diabetes mellitus
29. Elevation of percutaneous biopsy
30. Analysis of the plasminogen activator activity of the human glomerulus
31. Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers
32. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells
33. Cloning of cDNA coding for human tissue-type plasminogen activator and its expression in Escherichia coli
34. A general method of in vitro preparation and specific mutagenesis of DNA fragments: Study of protein and DNA interactions
35. Expression of decay accelerating factor mRNA and complement C3 mRNA in human diseased kidney
36. Localization of estrogen receptor messenger ribonucleic acid in rhesus monkey uterus by nonradioactive in situ hybridization with digoxigenin-labeled oligodeoxynucleotides
37. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells
38. Tissue-type plasminogen activator and its inhibitor in human glomerulonephritis
39. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin
40. Expression of plasminogen activator-inhibitor-1 (PAI-1) during cellular remodeling in proliferative glomerulonephritis in the rat
41. Expression of type 1 plasminogen activator inhibitor in renal tissue in murine lupus nephritis
42. Alterations in the extracellular matrix components in human glomerular diseases
43. Collagen distribution in focal and segmental glomerulosclerosis: An immunofluorescence and ultrastructural immunogold study
44. The glomerular distribution of laminin and fibronectin in glomerulonephritis
45. Platelet-derived growth factor and transforming growth factor-beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells
46. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor
47. Association of TGF-beta signaling in angiotensin II-induced PAI-1 mRNA upregulation in mesangial cells: Role of PKC
48. Induction of plasminogen activator inhibitor type 1 in murine lupus-like glomerulonephritis
49. Smad4/DPC4 and Smad3 mediate transforming growth factor-beta (TGF-beta) signaling through direct binding to a novel TGF-betaresponsive element in the human plasminogen activator inhibitor-1 promoter
50. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II
51. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells
52. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells
53. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis
54. Angiotensin in progressive renal diseases: Theory and practice
55. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction